Pfizer and Merck KGaA report that the FDA has accepted for priority review the partners PD-L1 for avelumab in patients with metastatic Merkel cell carcinoma.

Merkel skin cell carcinoma develops in the top layer of the skin and is a rare type of neuroendocrine tumor. These typically occur in the head and neck and are predominately found in older patients, or those with weakened immune systems.